Precision Bead (doxorubicin) / Boston Scientific - LARVOL DELTA

Key Updates in Lung Cancer in 2021 - Episode 19: Second-Line Treatment of SCLC (OncLive) - "John V. Heymach, MD, PhD: A space that's a little more challenging, with a lot more players but a lot less clarity, is the second-line small cell lung cancer space: what to do after CASPIAN or IMpower133. Vamsidhar Velcheti, MD:...The standard options are lurbinectedin, which got accelerated FDA approval recently based on a small study...Stephen Liu, MD: Right. ATLANTIS wasn't the perfect trial. It was a lower dose of lurbinectedin. It was a combination, not monotherapy. There's a phase 3 trial that's been agreed to in principle from the sponsors and the FDA that will look at lurbinectedin monotherapy at the dose we know...Sandip P. Patel, MD: To echo Stephen, this could be done in liquid biopsy, right?"

Video

CAR T-Cell Therapy as Second-Line Treatment in Large B-Cell Lymphomas: What Have We Learned From the Randomized BELINDA, TRANSFORM, and ZUMA-7 Trials? (THE ASCO POST) - "About 30% to 40% of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) experience relapse, and 10% are refractory to the regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. Most relapses occur during the first 2 years....At this point, it is unknown whether the overall survival of second-line chemotherapy responders who received high-dose chemotherapy and auto-HCT is inferior to that with CAR T-cell therapy. It remains to be seen whether the results of the two positive trials will change practice."

Online posting

Multiple Myeloma Treatment & Management (Medscape) - "In another randomized trial of lenalidomide plus high-dose dexamethasone (LD) versus lenalidomide plus low-dose dexamethasone (Ld) in newly diagnosed MM, Rajkumar found that although the overall response rate within the first 4 months favored LD, analysis at 1 year, overall survival was 96% in the Ld arm compared with 87% in the LD arm (p=0.0002). As a result, the trial was stopped, and patients on high-dose therapy were crossed over to low-dose therapy....In another study, Miguel et al found that the combination of pomalidomide with low-dose dexamethasone yielded a longer median progression-free survival (PFS) in 455 patients with refractory or relapsed and refractory MM than high-dose dexamethasone alone."

Media quote

Transarterial chemoembolization with 40-90 micron radiopaque drug-eluting microspheres for treatment of hepatocellular carcinoma (SIR 2019) - "Materials: A retrospective review was performed of all patients with unresectable HCC treated with 40-90 micron radiopaque drug-eluting beads (loaded with 50mg doxorubicin loaded per vial) from 9/2017 to 7/2018 as an outpatient procedure. Purpose: To assess the safety and efficacy of using 40-90 micron radiopaque drug eluting microspheres (M0 LUMI, BTG) for the treatment of hepatocellular carcinoma (HCC) during transarterial chemoembolization (TACE)."

Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Pain • Solid Tumor

Effects of hydrogen peroxide, doxorubicin and ultraviolet irradiation on senescence of human dental pulp stem cells. (PubMed, Arch Oral Biol) - "All three agents successfully triggered senescence in the cells. There was no significant difference in the capacity of the three donor's cells for senescence. To avoid premature senescence in stem cell in vitro, it is recommended to avoid unnecessary exposure of the cell to fluorescent and UV light. Moreover, to prevent ROS production, we recommend using a separate incubator with low oxygen content for cell culture, if possible."

Journal • CCND1

Tumor cell escape from therapy-induced senescence. (PubMed, Biochem Pharmacol) - "H460 non-small cell lung, HCT116 colon and 4T1 breast tumor cell lines induced into senescence by exposure to either etoposide or doxorubicin were able to recover proliferative capacity both in mass culture and when enriched for the senescence-like phenotype by flow cytometry (based on β-galactosidase staining and cell size, and a senescence-associated reporter, BTG1-RFP). Cells enriched for the senescence-like phenotype were also capable of forming tumors when implanted in both immunodeficient and immunocompetent mice. As chemotherapy-induced senescence has been identified in patient tumors, our results suggest that certain senescence-like phenotypes may not reflect a terminal state of growth arrest, as cells that recover with self-renewal capacity may ultimately contribute to disease recurrence."

Journal

Phase II Trial Using Combination of TACE and SBRT for Unresectable Single Large HCC: Interim Report (ASTRO 2019) - "Each DEB-TACE treatment utilized 1 vial of 100-300 micron LC Beads (BTG) loaded with 50mg of doxorubicin. Preliminary results from this Phase II trial show very promising response rates when combining TACE+SBRT in large, unresectable HCC with excellent OS, PFS, and CSS. These preliminary data are currently being confirmed in an expanded cohort. Table 1."

P2 data

BTG2 is a tumor suppressor gene upregulated by p53 and PTEN in human bladder carcinoma cells. (PubMed, Cancer Med) - "Camptothecin and doxorubicin treatments in RT-4 cells or transient overexpression of p53 into p53-mutant HT1376 cells induced p53 and BTG2 expression. Our results suggested that BTG2 functioned as a bladder cancer tumor suppressor gene, and was induced by p53 and PTEN. Modulation of BTG2 expression seems a promising way to treat human bladder cancer."

Journal